

**Supplementary Table S3.** Additional baseline patient and disease characteristics

Characteristic	N = 19
	No. of Patients (%)
<b>Ethnicity</b>	
Hispanic or Latino	0 (0%)
Non-Hispanic	19 (100%)
<b>Institution</b>	
Dana-Farber Cancer Institute	11 (57.9%)
Northwestern University Hospital	8 (42.1%)
<b>Hormone receptor status of metastatic tumor</b>	
ER and PR positive	1 (5.3%)
ER positive/PR negative	2 (10.5%)
ER negative/PR positive	1 (5.3%)
ER and PR negative	10 (52.6%)
Unknown	5 (26.3%)
<b>Adjuvant or neoadjuvant chemotherapy</b>	
Adjuvant or neoadjuvant anthracycline	6 (31.6%)
Adjuvant or neoadjuvant taxane	13 (68.4%)
Adjuvant or neoadjuvant trastuzumab	11 (57.9%)
Adjuvant or neoadjuvant pertuzumab	5 (26.3%)
Other Adjuvant or neoadjuvant therapy	10 (52.6%)
<b>Use of corticosteroids</b>	
Yes	5 (26.3%)
No	14 (73.7%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.